EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil

Neuro-Oncology

Volumn 9, Issue 3, 2007, Pages 364-369

  O'Neill, Brian Patrick ^a,c   Vernino, Steven ^b   Dogan, Ahmet ^a   Giannini, Caterina ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Department of Neurology ^*  (United States)

Author keywords

CNS; EBV; Lymphoproliferation; Mycophenolate; Primary CNS lymphoma

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HYDROXYCHLOROQUINE SULFATE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VIRUS RNA;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PATIENT SELECTION; SINGLE DRUG DOSE; VIRUS PATHOGENESIS;

AGED; AUTOIMMUNE DISEASES; BRAIN DISEASES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RNA, VIRAL;

EID: 34547416731     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2007-004     Document Type: Article

References (28)

1. Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol. 2006;133:124-140.
2. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005;23:61-7.
3. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44.
4. Mazhar D, Stebbing J, Bower M. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. Expert Rev Anticancer Ther. 2006;6:335-341.
5. Schiff D, O'Neill BP. Post-transplant lymphoproliferative disorders of the central nervous system. In Roos K, ed. Neurologic Complications of Organ Transplantation. Hagerstown, MD: CONTINUUM; 2004:48-60.
6. Phan TG, Kurtin PJ, O'Neill BP. Posttransplant primary CNS lymphoma. Neuro-Oncology. 2000;2:229-238.
7. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Pediatric Heart Transplant Study. Lancet. 2006;367:233-239.
8. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10:136-145.
9. Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76:930-937.
10. Vernino SA, Salamao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65:639-641.
11. Omiya R, Buteau C, Kobayashi H, Paya CV, Celis E. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol. 2002;169:2172-9
12. Kelleher CA, Dreyfus DH, Jones JF, Gelfand EW. EBV infection of T cells: potential role in malignant transformation. Semin Cancer Biol. 1996;7:197-207.
13. Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg. 2001;88:1330-1334.
14. Daddona PE, Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA. Adenosine deaminase deficiency with normal immune function: an acidic enzyme mutation. J Clin Invest. 1983;72:483-492.
15. Tosato G, Sgadari C, Taga K, et al. Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood. 1994;83:776-784.
16. Cohen PL. Autoimmunity and lymphoproliferation: two genes are worse than one. Mol Interv. 2002;2:427-430.
17. Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. Leukemia. 2004;18:238-242.
18. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen J. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997; 40:761-768.
19. Cattan S, Lemann M, Thuillier F, et al. 6-Mercaptopurine levels and study of blood lymphocyte subsets during azathioprine treatment of Crohn's disease. Gastroenterol Clin Biol. 1998;22:160-167.
20. Karamperis N, Koefoed-Nielsen PB, Brahe P, et al. Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays. Basic Clin Pharmacol Toxicol. 2006;98:569-574.
21. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80(2 suppl):S181-S190.
22. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol. 1991;33:175.
23. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol. 1996;24:59.
24. Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001;5:112-118.
25. Gao SZ, Chaparro SV, Perloth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant. 2003;22:505-514.
26. Caillard S, Dharnidharka V, Agodoa L, Bohen N, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233-1243.
27. Waldman MA, Callen JP. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol. 2004;51(2 suppl):S124-S130.
28. Dasgupta N, Gelber AC, Racke F, Fine DM. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus. 2005;14:910-913.